Full Text Available
Note: Clicking the button above will open the full text document at the original institutional repository in a new window.
Survival Outcomes and Prognostic Factors in Patients with Metastatic Colorectal Cancer Treated First-Line mFOLFOXIRI Plus Bevacizumab: A Real-World Study in Vietnam
Saved in:
| Published in: | OncoTargets and Therapy |
|---|---|
| Format: | Online Article RSS Article |
| Published: |
2026
|
| Subjects: | |
| Tags: |
No Tags, Be the first to tag this record!
|
Similar Items: Survival Outcomes and Prognostic Factors in Patients with Metastatic Colorectal Cancer Treated First-Line mFOLFOXIRI Plus Bevacizumab: A Real-World Study in Vietnam
- The prognostic value of baseline hematological parameters of peripheral blood in metastatic gastric cancer treated with apatinib
- Histopathologic growth patterns as prognostic factor for survival in patients with colorectal liver metastases
- Revised tumor burden score for prognostic stratification in metastatic colorectal cancer patients receiving immunotherapy: a retrospective study
- Association Between Blood Transfusion and Survival Outcomes in Metastatic Cutaneous Melanoma Treated with Nivolumab
- Maintenance Metronomic Chemotherapy in Treatment of Metastatic Colorectal Cancer
- First-Line Tislelizumab Plus Chemotherapy for Advanced or Metastatic Squamous Non-Small Cell Lung Cancer: 4-Year Long-Term Follow-Up from RATIONALE-307